A B S T R A C T To determine whether the phosphaturic response to circulating parathyroid hormone (PTH) is exaggerated in patients with familial x-linked hypophosphatemic vitamin D-resistant rickets (FHR), we examined the phosphaturic response to parathyroid extract (PTE) (administered intravenously in the posthypercalcemic state) in two unrelated adult hemizygotes with FHR. In these two patients whose plasma concentration of PTH was normal (determined by radioimmunoassay), neither vitamin D nor phosphate therapy had been given during the past 10 yr. Two normal men and a hypophosphatemic man with intestinal malabsorption, hypocalcemia, and osteomalacia served as control subjects. In all subjects, calcium gluconate was administered intravenously from 6 p.m. to 12 midnight at a rate that maintained the concentration of serum calcium at 13-15 mg/ 100 ml during the administration of calcium. When normocalcemia had recurred the next morning, and the plasma PTH concentration and urinary excretion of cyclic 3',5'-AMP were reduced, PTE was administered intravenously at successively increasing rates of 0.1, 0.4, and 0.8 U/kg per h, each rate lasting 90 min. Minutes after the initiation of PTE in the affected hemizygotes, fractional excretion of filtered phosphate increased from negligible values to values strikingly greater than those of similarly studied control subjects and plateaued at strikingly greater values throughout further administration of PTE. This phenomenon of exaggerated phosphaturia could not be attributed to volume expansion, decreases in serum concentration of calcium during the study, differences in percent of administered calcium Dr. Short's current address is the Department of Medicine, Stanford University, Palo Alto, Calif. 94305.
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Received for publication 16 October 1974 and in revised form 3 March 1976. retained, or hemodynamic changes. Only the phosphaturic response to PTE appeared to be exaggerated. At any cumulative dose of PTE, urinary excretion of cyclic 3',5'-AMP in the hemizygotes was indistinguishable from that of control subjects. The findings in this study suggest that in patients with FHR, circulating PTH is required for the genetically transmitted abnormality to be physiologically expressed as a reduction in net renal reabsorption of phosphate, and that this physiological expression of the genetic abnormality is expressed fully at normal or nearly normal circulating levels of PTH. INTRODUCTION Familial x-linked hypophosphatemic rickets (FHR)' is an x-linked dominant genetic disease characterized by lifelong hypophosphatemia, increased renal clearance of phosphate, normocalcemia, and, in children, rickets resistant to treatment with vitamin D in amounts predictably curative of rickets caused by simple deficiency of vitamin D ( 1, 2) . In patients with FHR, reduced renal tubular reabsorption of inorganic phosphate (TRP) is not necessarily associated with a demonstrable increase in the concentration of circulating parathyroid hormone (PTH) (3) (4) (5) (6) . Glorieux and Scriver proposed that in FHR the parathyroid-hormone-responsive component of renal phosphate transport is genetically altered in a way that renders it physiologically unresponsive to circulating PTH (7) . This proposal is based on their observations that in affected hemizygotes, the measured magnitude of reduction in renal phosphate reabsorption remained unchanged over a 10-fold increase in plasma concentration of endogenous PTH (3), despite intravenous administration of a large amount of PTH (7) . They confirmed previous observations that experimental hypercalcemia is attended by an increase in the value of TRP (8) (9) (10) (11) , and interpreted this as evidence that induced hypercalcemia per se increased renal phosphate reabsorption via a transport system independent of that normally responsive to PTH. Yet, an increased renal responsiveness to the phosphaturic effect of normal (3) (or even reduced, [4] ) concentrations of circulating PTH could explain the characteristic reduction of TRP in patients with FHR (12) as well as the increase in TRP that attends sustained experimental hypercalcemia in these patients (8) (9) (10) (11) (13, 14) .
METHODS
Study subjects. Two unrelated, previously unreported, adult male patients with x-linked hypophosphatemic rickets were studied (Table I , Fig. 1 (6) . The human PTH used as a reference standard was derived from purification of parathyroid adenomas and has been previously characterized in relation to purified bovine PTH and the antibody (PG-I) (20, 21 (Fig. 3 ). Yet with phosphate loading, the maximal value of FE P04 attained in the hemizygotes during administration of PTE was 53±3.7% (±+1 SD), compared to 23.9+2.3% in a normophosphatemic, normal control subject and 40±11.6% in the same hemizygotes without phosphate loading (Fig. 4) Mean value (±1 SD) of three successive clearance periods during infusion of PTE at 0.8 U/kg per h, at which time the value of fractional excretion of filtered phosphate (CPO4CIN X 100) had reached a plateau (see Fig. 1 ).
trol subject (Table III) . Similarly, serum calcium was within the normal range in each hemizygote and changed no more than 0.5 mg/100 ml throughout the study.
In all subjects studied, the urinary excretion rate of cAMP was reduced until PTE was administered and in- creased progressively thereafter. At any cumulative dose of PTE, the rates of excretion of cAMP in the hemizygotes were similar to those of the other study subjects (Figs. 2 and 3 ). When PTE was not administered during posthypercalcemic periods temporally comparable to those in which PTE was administered, fractional phosphate excretion and urinary excretion of cAMP remained reduced, in both the hemizygotes (irrespective of phosphate loading) and in the normal subjects (Figs. 5 and  6) .
At the lower rates of PTE administration, 0.1-0.4 U/kg per h, and before significant changes in the GF rate or apparent renal plasma flow occurred, the values of fractional excretion of phosphate in the hemizygotes had increased significantly and were significantly greater than those in the control subjects (Figs. 2, 3, and 7) . When PTE was administered at the rate of 0.8 U/kg per h, both the GF rate and apparent renal plasma flow increased significantly in all studies (Table II) . At S not increase. In the pre-PTE control period, hemizygotes excreted significantly less calcium than the normal control subjects; the fractional excretion of Ca was 1.09±0.49 and 1.55±0.37%, respectively (P < 0.025).
With administration of PTE, urinary excretion of calcium decreased somewhat in the normal control subjects but not in the hemizygotes. Urinary excretion of bicarbonate increased significantly in both normal control subjects and hemizygotes when PTE was administered, but the increase in the hemizygotes was significantly less than in the normal control subjects in whom the maximal fractional excretion of filtered bicarbonate attained was only 1.6%. With administration of PTE, urinary excretion of ammonium remained fixed in the hemizygotes and decreased somewhat in control subjects. In the hemizygotes, excretion of titratable acid increased from 12.9±3.2 to 35.9+ 3.7 umol/100 ml GF when PTE was administered with sodium phosphate, and to 27.1±3.4 /Amol/100 ml with PTE alone. In the control subj ects, excretion of titratable acid did not change significantly when PTE was administered. In all studies, the arterial plasma bicarbonate concentration remained normal and did not change significantly when PTE was administered.
Glucosuria did not occur in any study. In all studies of the hemizygotes, the urinary excretion rate of alphaamino nitrogen remained normal throughout and increased significantly only when PTE was administered at a rate of 0.8 U/kg per h and then to rates not significantly greater than those occurring in the normal subj ects. Before induction of hypercalcemia, the plasma concentration of iPTH in the hemizygotes, 424±125 pg/ml (+ 1 SD), was not significantly different from that of Exaggerated Phosphaturic Response to PTE in FHR 159 the normal control subjects, 484±83 pg/ml (±1 SD), a value in the normal range established with the antibody used (6) . After the occurrence of hypercalcemia, the mean decrease in plasma concentration of iPTH in the hemizygotes, 134+69 pg/ml, was not significantly different from that in the normal control subjects, 187±95 pg/ml.
DISCUSSION
The results of the present study indicate that in patients with FHR the phosphaturic response to circulating PTH is exaggerated. When PTE was intravenously administered to two adult hemizygotes with FHR in the posthypercalcemic state, FE P04 increased within minutes from a negligible value to values significantly greater than those of similarly studied control subjects, even though the filtered loads of phosphate in the hemizygotes were significantly lower than in the normal control subjects. The greater values of FE P04 in the hemizygotes reflected rates of renal reabsorption of phosphate that were significantly less than those obtaining with identical cumulative doses of PTE in hypophosphatemic and normophosphatemic control subjects. The abrupt and striking increase in FE P04 that attended administration of PTE was clearly caused by an increase in the circulating level of renoactive PTH, and the increase would appear to have been from a reduced level. In both hemizygotes and control subjects, FE P04 and urinary excretion of cAMP remained reduced long after termination of experimental hypercalcemia unless or until PTE was administered, whereupon the excretion of both cAMP and phosphate increased within minutes with no discernible difference in their times of onset. At any cumulative dose of PTE, urinary excretion of cAMP in the hemizygotes was indistinguishable from that of control subjects. An exaggerated phosphaturic response to PTE persisted in the patients with FHR throughout the 4i h of PTE administration and could not be related to differences between patients and control subjects in extracellular volume (22, 23) , serum calcium concentration during the study, percent of administered calcium retained, or renal hemodynamic changes. Moreover, only the phosphaturic response to PTE appeared to be exaggerated.
It might be argued that the patient with intestinal malabsorption, vitamin D deficiency, hypocalcemia, and secondary hyperparathyroidism was not an ideal hypophosphatemic control subject, since the phosphaturic response to PTE might be blunted by such consequences of malabsorption as contraction of extracellular fluid volume (24, 25) , depletion of potassium (22) , and systemic acidosis (23) . But none of these (nor hypomagnesemia) was present in this patient at the time of study, nor had they been present for at least 1 wk beforehand.
Although several observations suggest that vitamin D deficiency per se might act to dampen net renal tubule reabsorption of phosphate (26, 27) , virtually complete net renal tubular reabsorption of phosphate has been observed in the vitamin D-deficient, hypophosphatemic, phosphate-depleted rat (28) . Presumably, the "blunted" response to PTE in the hypophosphatemic, presumably phosphate-depleted control subject was a consequence of hypophosphatemia per se (29, 30) .
The known and likely determinants of renal phosphate transport (with the obvious exceptions of the genetic defect and the hypophosphatemic state) were demonstrably equalized in the patients and normal control subjects of the present study. Only men 25 yr of age or older were studied and none had received phosphate therapy, vitamin D, or any of its analogues or derivatives for at least 1 yr before study. Accordingly, interpretation of the physiological data is not complicated by whatever effects these agents or those metabolic events attending somatic growth might have on renal tubular transport of phosphate. When PTE was administered, the patients with FHR were not different from the normal control subjects with respect to posthypercalcemic status, plasma concentration of PTH, renal tubular reabsorption of phosphate (approximately 100%), serum concentration of calcium (normal), urinary excretion of cAMP, receipt of PTE on dose per unit weight basis, renal hemodynamics (as judged by measurements of the clearance of inulin and paraaminohippuric acid), and nonoccurrence of phosphaturia or increased cAMP excretion during temporally comparable posthypercalcemic periods in which PTE was not administered. The results of the studies thus provide the first convincing evidence that in the patients with FHR the phosphaturic response to PTH is exaggerated, and strongly suggest that the phenomenon reflects the genetic defect.
In two previously described boys with hypophosphatemic vitamin D-resistant rickets, the possibility that the phosphaturic response to administered PTE is exaggerated in patients with FHR can be entertained, but a definitive conclusion cannot be made because of uncertainties of diagnosis, experimental design, and metabolic state of the patients. In a 6-yr-old boy with hypophosphatemic vitamin D-resistant rickets studied by Fraser et increase in renal blood flow, which almost invariably occurs with large doses of PTE, could not be excluded since the only index of renal hemodynamics reported was the clearance of creatinine. Studies of control subjects were not reported. Given the uncertain growth status of the patient, it is problematic whether an appropriate control study could have been carried out. In a pubescent boy with hypophosphatemic vitamin D-resistant rickets studied by Magid et al. (13) at age 14 and 15 yr, after prolonged therapy with massive amounts of vitamin D2 (8,000,000 IU day) had been discontinued for 6 wk and 1 day, respectively, PTE was administered intravenously as single injections of either 200 or 25 U, with and without prior induction of hypercalcemia. When PTE was administered, FE P04 (clearance of phosphate/clearance of creatinine) increased transiently to values greater than those occurring in a normal subject of unspecified age, size, and growth status studied in a similar way. Measurements of renal blood flow were not reported. The patient may not have had classical FHR, since FE P04 did not decrease after sustained hypercalcemia. Familial involvement could not be shown except for the patient's possibly affected mother in whom neither a posthypercalcemic reduction in FE P04 nor an exaggerated phosphaturic response to PTE could be demonstrated.
The present demonstration in the hemizygote that the value of FE P04 plateaued after administration of 1.0 U/kg of PTE, despite further PTE administration (to 2.0 U/kg) and continued increase in urinary cAMP excretion, suggests the presence of a residual component of net phosphate reabsorption that is not responsive to PTE or conditioned by cAMP response, at least in the concentrations of PTE achieved in this study. This residual reabsorptive capacity was 34.7±+1.6 jmol/100 ml GF with phosphate loading and 39.7±3.0 tmol/100 ml GF without phosphate loading, a nonsignificant difference. The data of Glorieux and Scriver suggest the presence of a similar residual component of net phosphate transport in hemizygotes with a capacity of approximately 50 zmol/100 ml GF (7) .
At any cumulative dose of PTE in hemizygotes, urinary excretion of cAMP was indistinguishable from that of control subj ects irrespective of serum phosphate concentration, in accord with the findings of Glorieux and Scriver (7) . In the hemizygote, the finding that the doseresponse relationship between administered PTE and cAMP excretion is indistinguishable from that of control subjects suggests that in patients with FHR the renal response to PTE is not abnormal with respect to membrane binding of PTE, adenyl cyclase activation (32) , and cAMP production (33) .
An exaggerated phosphaturic response to circulating PTH need not reflect an "abnormal" response of the renal tubule to PTH (or cAMP) at the cellular level of action of this hormone. Specifically, the exaggerated phosphaturic response to PTE need not reflect a state of hyperresponsiveness of those phosphate transport systems normally responsive to PTH. If in FHR the genetically transmitted abnormality acted to reduce reabsorption of phosphate in the proximal nephron by a PTHunresponsive mechanism, and if a normally large rate capacity for phosphate reabsorption in the distal nephron were inhibited by normal levels of PTH (34) (35) (36) (37) (38) (39) (40) (41) , the magnitude of phosphaturia would be greater in patients with FHR than in normal subjects at similar filtered loads of phosphate and circulating levels of PTH, even though responsiveness of the renal tubule to PTH was normal at the cellular level. The difference in rate of phosphate excretion would reflect the difference in rate of delivery of phosphate out of the proximal nephron. If, in the absence of PTH, the rate capacity for phosphate reabsorption in the distal nephron were sufficiently great, net renal reabsorption of filtered phosphate in FHR might be complete despite the persistence of a substantially reduced net reabsorption rate of phosphate in the proximal nephron. In this circumstance, PTH could be said to "unmask" the abnormality of the PTH-unresponsive phosphate transport mechanism of the proximal nephron. It is apparent that the unmasking of an abnormality of the PTH-unresponsive phosphate transport mechanism in the proximal nephron might also be contributed to (or even accounted for) by the effect of PTE to further decrease reabsorption of phosphate in the proximal nephron.
The results of the present study are also consistent with the possibility that in patients with FHR, a PTHresponsive phosphate transport mechanism in the proximal and(or) distal nephron is genetically altered such that it is hyperresponsive to the phosphaturic effect of PTH. Such hyperresponsiveness might stem from a genetically determined defect in one of the determinants of the PTH-responsive phosphate transport system or in the transport system per se. In patients with FHR, the increase in intracellular concentration of cAMP induced in the renal tubule by subphysiological amounts of PTH might be greater than that induced in normal subjects. The finding of a similar, PTH-induced increase in urinary excretion of cAMP in the patients with FHR and control subjects provides no support for this possibility but does not exclude it. In FHR, hyperresponsiveness to the phosphaturic response to PTH could reflect a genetic defect in a component of the phosphate transport system that normally acts to dampen the phosphaturic response to PTH-induced increase in intracellular concentration of cAMP.
In patients with FHR, a genetically determined defect in the metabolism of vitamin D could underlie the Exaggerated Phosphaturic Response to PTE in FHR exaggerated phosphaturic response to PTH. 25 (OH) D3, the principal initial metabolite of vitamin D3 (42) , can act directly on the renal tubule to increase its net phosphate reabsorption (27, 43, 44) and, in parathyroidectomized rats, to blunt the phosphaturic response to administered PTH (43) . Although it is not clear that 25 (OH) D3 or its metabolite 1,25 (OH)sD3 (which is made exclusively in the renal cortex) (45-47) acts directly on the PTH-responsive phosphate transport system, 25 (OH) D3 acts to enhance renal reabsorption of phosphate in the rat only in the presence of PTH (43, 44) . This suggests that PTH may act to convert 25-(OH)D3 to a metabolite normally required for enhanced renal transport of phosphate. PTH is known to enhance conversion of 25 (OH) D3 to 1,25 (OH)2D3 (48, 49) and possibly to 24,25(OH)2D3 as well in some circumstances (50) . The PTH-responsive phosphate transport system might then normally be modulated by 25 (OH) D3 or one of its metabolites such as to dampen the phosphaturic effect of PTH. If so, hyperresponsiveness to the phosphaturic effect of PTH in patients with FHR might reflect a genetic defect that acts to prevent or dampen the conversion of 25 (OH) D3 to a metabolite that normally acts on the PTH-responsive transport system to blunt the phosphaturic effect of PTH.
